SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “outperform” rating reaffirmed by Oppenheimer in a report released on Thursday, Benzinga reports. They presently have a $12.00 price objective on the stock. Oppenheimer’s price objective suggests a potential upside of 341.18% from the company’s previous close.
A number of other equities research analysts also recently issued reports on the company. Brookline Capital Management began coverage on SAB Biotherapeutics in a research report on Friday, June 7th. They issued a “buy” rating and a $8.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, August 12th. Finally, Chardan Capital reiterated a “buy” rating and set a $25.00 price target on shares of SAB Biotherapeutics in a report on Monday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, SAB Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $12.75.
Read Our Latest Stock Analysis on SABS
SAB Biotherapeutics Stock Performance
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.34. The business had revenue of $0.26 million for the quarter. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%. As a group, sell-side analysts anticipate that SAB Biotherapeutics will post -3.59 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of SABS. First PREMIER Bank purchased a new stake in SAB Biotherapeutics during the 2nd quarter valued at about $60,000. Commodore Capital LP purchased a new position in shares of SAB Biotherapeutics in the 4th quarter worth $1,259,000. BVF Inc. IL bought a new stake in shares of SAB Biotherapeutics during the 4th quarter valued at about $6,310,000. Finally, RTW Investments LP purchased a new stake in SAB Biotherapeutics during the fourth quarter valued at approximately $6,310,000. 7.82% of the stock is currently owned by institutional investors.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.
Featured Stories
- Five stocks we like better than SAB Biotherapeutics
- Stock Market Upgrades: What Are They?
- 3 Leveraged ETFs to Multiply Returns
- Industrial Products Stocks Investing
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- Options Trading – Understanding Strike Price
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.